In the aggressive HER2-positive cancer subtype, FMRP expression levels were lower than in the controls and lower FMRP levels were associated with a higher risk of distant relapse (Exact Fisher test, p = 0.000; OR = 7.357; 95% CI = 3.2–16.7). The gene discussed is ERBB2; the disease is cancer.